Spironolactone
Product Images NDC 70934-367

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 70934-367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

70934 367 30 Master Bottle Label Approval Rev A 05 19

70934 367 30 Master Bottle Label Approval Rev A 05 19
Spironolactone Tablets USP 100 mg package label by Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label indicates 30 tablets, prescription use only, and provides storage instructions to keep at controlled room temperature (20°-25°C). It includes warnings to keep out of reach of children and protect from light. The label also features the product NDC 70934-367-30 and mentions lot and expiration date placeholders.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival curve comparing Spironolactone and Placebo groups over 48 months. The y-axis represents probability, and the x-axis shows time in months. The curve for Spironolactone is higher indicating greater probability throughout, with a significant log-rank p-value less than 0.001.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot chart depicting subgroup analysis of Spironolactone versus placebo. It shows hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups based on age, sex, race, LVEF%, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, and use of digoxin, ACE inhibitors, or beta blockers. The chart compares treatment effects, indicating points favoring Spironolactone or placebo.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure diagram of spironolactone showing its molecular framework with labeled functional groups and bonds, as provided in the product data for Spironolactone by Denton Pharma, Inc. dba Northwind Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.